Having trouble viewing this email? View in your browser.
ESCMID Logo

30 July 2019
WEEKLY NEWS

Dear colleagues,

Please find below the latest edition of ESCMID Weekly News.

With kind regards,

ESCMID Executive Office.

 

5th ESCMID Conference on Vaccines: Vaccines against respiratory infections: new insights and new vaccines

The 5th ESCMID Conference on Vaccines will take place in Bilbao, Spain. An interesting programme is waiting for specialists or physicians in training in infectious diseases, clinical microbiology, hygiene, public health, vaccinology and other disciplines dealing with all aspects of vaccination.

The conference has been awarded with a total of 17 CME points. 

Breakdown of ECMEC®s per day:

06.09.2019 - 7.00

07.09.2019 - 6.00

08.09.2019 - 4.00

We hope to see you all in Bilbao in September.

› Read more

Shaping the future of ESCMID: the call for new ESCMID Executive Committee members is open!

At the end of 2019 elections will be held among the membership to fill three (out of eight) positions in the ESCMID Executive Committee. Don’t miss the opportunity to shape the future of ESCMID by nominating new ESCMID Executive Committee members! To nominate a candidate please complete this form and submit it latest by 31 August 2019.

› Read more

2020 ESCMID Young Investigator Awards for Research in Clinical Microbiology and Infectious Diseases: the call will open soon!

In 2020, ESCMID will again offer Young Investigator Awards for research in clinical microbiology and infectious diseases to recognize outstanding research by younger colleagues in these fields. The call will open on 8 August 2019 and will close on 8 October 2019. Click here to find out more

› Read more
 

Second ESCMID Course on Precision Medicine (26 – 28 September 2019, Rome, Italy): register now!

Precision medicine has become a key-stone to improve the patient’s management and increase recovery rates. The Second ESCMID Course on Precision Medicine will take place in Rome, Italy, next September. Don't miss the opportunity to participate!

Upon completion of this course, participants will be able to:

  • Understand the pharmacokinetic and epidemiologic heterogeneity in patient populations traditionally excluded from clinical studies such as the critically ill; the elderly; those with renal insufficiency; the obese; and female patients.
  • Understand the evidence (or lack thereof) for medical decision-making in these populations.
  • Explore both the limits and the strengths of current “one-size-fits-all” guidelines.
  • Understand the clinical implications of variations in local epidemiology, microbiota, and regional perceptions regarding antimicrobial use.
  • Explore the clinical evidence for recommended durations of antimicrobial therapy.
  • Understand the variation in pharmacokinetics across populations

Please click here to complete your registration!

› Read more
 

CMI Highlight: Mediastinitis in the intensive care unit patient: a narrative review

B. Pastene et al, assessed with this review are to highlight the clinical features of mediastinitis, to attempt to define each clinical scenario, to describe the pathogens responsible, and ,finally, to describe the medical and surgical treatments.

Mediastinitis is a rare but severe infection, defined as an inflammation of the connective tissues and structures within the mediastinum. Due to its proximity to vital structures, mediastinitis represents a highly morbid pathological process associated with a high risk of mortality. In most cases mediastinitis requires treatment in the intensive care unit.

The authors performed a literature search of the PubMed and Cochrane libraries, limited for articles published between January 2003 and December 2018, reporting on acute mediastinitis.

The term covers different entities of different aetiologies including deep sternal wound infection related to sternotomy; oesophageal perforation or anastomosis leakage; and finally descending necrotizing mediastinitis, often secondary to oropharyngeal abscess. The responsible pathogens and therefore subsequent management depends on the underlying aetiology. Empirical antimicrobial therapy should cover the suspected microorganisms while surgery and supportive measures should aim to reduce the inoculum of pathogens by providing adequate drainage and debridement.

Literature concerning mediastinitis in the intensive care unit is relatively scarce.

B. Pastene et al. Gathered evidence and reviewed the different causes and treatment options for acute mediastinitis, with a focus on microbiological epidemiology. Future research in larger cohorts is needed to better understand the treatment of this difficult disease.

› Read more
 

ESCMID Guideline Highlight: The draft version of the "ESCMID Guideline Manuals" has now entered into the public consultation phase.

This document has two major aims: 
(1) an outline of ways ESCMID guidelines can be proposed and developed; 
(2) a guide for drafting group (DG) chairs and members for the guideline development process. 

The ESCMID members wishing to comment on the manuscript need to express their commitment following this link to receive the confidential manuscript.

The deadline for providing feedbacks and comments on the confidential manuscript is 28th of August 2019.

Please be aware that your comments and the authors’ responses to the comments will be made available online once the Medical guideline document is published.

If you have any questions, please address them to guidancedocuments@escmid.org

› Read more
 

Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease is open for public consultation

The draft version of the "Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease" has now entered into the public consultation phase.
The guidance document is a result of the concerted efforts of experts across Europe, the Infectious Diseases Society of America (IDSA), the American Academy of Neurology (AAN), and the American College of Rheumatology (ACR).

The ESCMID members wishing to comment on the manuscript need to express their commitment following this link, to receive the confidential manuscript.The deadline for providing feedbacks and comments on the manuscript is 26th of August 2019

Please be aware that your comments and the authors’ responses to the comments will be made available online once the guideline is published.

If you have any questions, please address them to guidancedocuments@escmid.org

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Switzerland
Phone +41 61 5080 173
info@escmid.org
www.escmid.org
Follow ESCMID
Visit us on LinkedIn Visit us on YouTube
 
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.